Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology, neurodegeneration, ophthalmology, dermatology, and Immunology. The company offers Elepsia XR, a formulation of levetiracetam that is an anti-epileptic agent to treat epilepsy disorder; Xelpros, a latanoprost ophthalmic emulsion for the treatment of open-angle glaucoma or ocular hypertension; and Phenobarbital injection for the treatment of neonatal seizures. In addition, it is developing SDN-037, a formulation of difluprednate for the treatment of inflammation and pain associated with ocular surgery that is in phase 3 clinical trial; PDP-716 to treat glaucoma, which is in phase 3 clinical trial; Vodobatinib (SCO-088) for the treatment of resistant chronic myelogenous leukemia that has completed a part A of the Phase 1 study; Vodobatinib (SCC-138), which is in phase 2 clinical trial to treat Parkinson's disease; SCD-044 for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial; and SCO-120 for the treatment of hormone receptor-positive, human epidermal receptor 2 negative, and metastatic breast cancer, which is in phase 1 clinical trial. The company was incorporated in 2006 and is based in Mumbai, India.
Stock data | 2023 | Change |
---|---|---|
Price | $2.69 | N/A |
Market Cap | $766.36M | N/A |
Shares Outstanding | 284.70M | 8.19% |
Employees | 407.00 | N/A |
Shareholder Equity | 5.13B | 1542.16% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | -0.34 | N/A |
P/S Ratio | 26.92 | N/A |
P/B Ratio | 0.15 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -0.0052 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $28.47M | N/A |
Earnings | -$26.54M | N/A |
EPS | -7.82 | N/A |
Earnings Yield | -2.91 | N/A |
Gross Margin | 0.2814 | N/A |
Operating Margin | -0.9366 | N/A |
Net income margin | -0.9322 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $98.96M | N/A |
Total Debt | $1.87M | N/A |
Cash on Hand | $47.98M | N/A |
Debt to Equity | 0.0074 | -92.23% |
Cash to Debt | $25.68 | 15679.69% |
Current Ratio | $2.54 | 512.56% |